Compare UTHR & BNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTHR | BNTX |
|---|---|---|
| Founded | 1996 | 2008 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5B | 24.2B |
| IPO Year | 1999 | 2019 |
| Metric | UTHR | BNTX |
|---|---|---|
| Price | $522.02 | $91.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 13 |
| Target Price | ★ $567.57 | $133.46 |
| AVG Volume (30 Days) | 363.4K | ★ 808.2K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.07 | N/A |
| EPS | ★ 13.07 | N/A |
| Revenue | ★ $1,483,300,000.00 | N/A |
| Revenue This Year | $6.39 | N/A |
| Revenue Next Year | $14.18 | $3.37 |
| P/E Ratio | $89.12 | ★ N/A |
| Revenue Growth | ★ 2.38 | N/A |
| 52 Week Low | $292.34 | $79.81 |
| 52 Week High | $609.35 | $124.00 |
| Indicator | UTHR | BNTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.00 | 47.46 |
| Support Level | $518.82 | $89.18 |
| Resistance Level | $542.66 | $94.10 |
| Average True Range (ATR) | 12.70 | 2.64 |
| MACD | -0.57 | -0.06 |
| Stochastic Oscillator | 56.12 | 45.89 |
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.